Accueil・Liste d'Actions・AbbVie Inc

AbbVie Inc

Ouvert

SecteurSoins de santé

264.52 -0.26

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

261.36

Max

265.45

Chiffres clés
By Trading Economics
Revenu	2.9B 3.6B
Ventes	2B 17B
P/E Moyenne du Secteur	70.516 57.371
BPA	3.65
Rendement du dividende	2.74
Marge bénéficiaire	21.283
Employés	57,000
EBITDA	5B 8.7B

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+5.71% upside

Dividendes
By Acuity
Rendement du dividende Moyenne du Secteur	2.74% 2.23%
Prochains Résultats	30 oct. 2026
Date du Prochain Dividende	13 nov. 2026
Date du Prochain Détachement de Dividende	14 oct. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-12B 442B
Ouverture précédente	264.78
Clôture précédente	264.52

Sentiment de l'Actualité

By Acuity

51%

49%

275 / 340 Classement par Healthcare

AbbVie Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 août 2026, 20:06 UTC

News

AbbVie Inc is set to present new data on its bispecific antibody at the 2026 World Conference on Lung Cancer, boosting investor sentiment. Shares are higher today.

20 août 2026, 19:31 UTC

News

Correlated Moves

AbbVie shares are lower today, despite Piper Sandler raising its price target to $303 from $298. The decline aligns with broader sector weakness.

19 août 2026, 23:01 UTC

AbbVie Inc. is lower in after-market trading, driven by declines in the Biotechnology sub-sector. Recent sessions had shown upward momentum.

18 août 2026, 23:51 UTC

Abbvie Inc shares are trading higher in after-market hours, reflecting resilience amid elevated bond yields and inflation concerns. The stock remains above its 20-day moving average.

17 août 2026, 23:51 UTC

AbbVie Inc shares are trading lower in after-market hours amid weak broader market sentiment influenced by geopolitical tensions and rising crude oil prices.

14 août 2026, 19:46 UTC

Social Media

AbbVie Inc has begun a Phase 2 trial for ABBV-295, yet shares are lower amid negative market sentiment from a decline in U.S. retail sales.

13 août 2026, 23:21 UTC

Abbvie Inc shares are lower in after-market hours, with no specific news identified for the decline. Initial jobless claims rose unexpectedly today.

12 août 2026, 20:06 UTC

News

Macro Event

AbbVie Inc. shares are lower today, continuing a decline since Tuesday's close, despite FDA acceptance of a BOTOX Cosmetic application for jawline contouring.

11 août 2026, 20:06 UTC

News

AbbVie shares are higher as BNP Paribas raises the price target to $247. Allergan Aesthetics enhances its Partner Privileges program to boost customer engagement.

10 août 2026, 23:06 UTC

AbbVie Inc shares are lower in after-market hours amid mixed market sentiment influenced by geopolitical tensions and President Trump's comments on economic pressure.

7 août 2026, 23:01 UTC

AbbVie Inc shares are trading lower in after-market hours, with no specific news identified to explain the decline. The stock remains near its one-month low.

6 août 2026, 20:06 UTC

Social Media

AbbVie Inc shares are lower as bearish sentiment grows in biotech and pharma sectors, with discussions highlighting potential resistance and negative momentum patterns.

5 août 2026, 19:26 UTC

News

Event

AbbVie shares are higher as Canada's Drug Agency recommends UBRELVY for migraine treatment. The company also raised its 2026 revenue outlook to $67.60 billion.

4 août 2026, 23:01 UTC

Event

AbbVie Inc shares are higher in after-market hours following a recommendation for UBRELVY® reimbursement by Canada's Drug Agency, enhancing patient accessibility.

3 août 2026, 23:06 UTC

News

Canaccord Genuity raised its price target for AbbVie to $290, contributing to a modest increase in shares during after-market hours.

31 juil. 2026, 20:04 UTC

News

Event

AbbVie Inc. lowered its 2026 adjusted earnings guidance, now projecting $13.87 to $14.07 per share, contributing to a decline in its stock price today.

30 juil. 2026, 22:41 UTC

Social Media

Event

AbbVie Inc announced JUVÉDERM® Day for August 19, 2026, boosting shares higher in after-market hours amid strong trading activity.

29 juil. 2026, 23:06 UTC

Event

The European Commission approved RINVOQ® for severe alopecia areata, contributing to higher after-market hours trading for Abbvie Inc. Shares remain above their 20-day moving average.

28 juil. 2026, 23:06 UTC

AbbVie Inc. shares traded higher in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

27 juil. 2026, 19:46 UTC

Social Media

AbbVie Inc. shares are trading lower amid a broader market decline, influenced by falling crude oil prices despite recent social media discussions on its 52-week high.

24 juil. 2026, 23:51 UTC

Social Media

Abbvie shares are trading lower in after-market hours despite a presentation on ABBV-CLS-484, a novel cancer immunotherapy inhibitor.

23 juil. 2026, 10:16 UTC

AbbVie Inc shares are trading lower in pre-market hours, with no specific news identified to explain the movement. The stock remains within its one-month trading range.

22 juil. 2026, 23:06 UTC

AbbVie Inc shares are modestly higher in after-market trading. No specific news was identified to explain the movement, amid broader market volatility.

21 juil. 2026, 19:06 UTC

Abbvie Inc. is higher today, supported by broader market gains and optimism in the semiconductor sector after TSMC's potential price increases by 2027.

20 juil. 2026, 23:01 UTC

AbbVie Inc. shares are lower in after-hours trading following a decline from earlier gains, remaining above the 20-day moving average.

Comparaison

Variation de prix

AbbVie Inc prévision

Objectif de Prix

By TipRanks

5.71% hausse

Prévisions sur 12 Mois

Moyen 280.1 USD 5.71%

Haut 303 USD

Bas 225 USD

Basé sur 23 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

23 ratings

Achat

Maintien

Vente

Basé sur 23 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

275 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.